No Data
beigene (06160.HK) achieved adjusted operating profit of 66 million US dollars in the third quarter. sales of Bavencio in europe increased significantly by 217%
Gelonghui November 12th | Beigene (06160.HK) announced that as of September 30, 2024, the company's total revenue reached 1.002 billion US dollars, compared to 0.781 billion US dollars in the same period in 2023, mainly benefited from the sales of Baiyuezhe in the USA and Europe, which increased by 87% and 217% respectively. In the third quarter of 2023, the company regained the global commercialization rights of Axitinib and Baizean, confirming the remaining deferred revenue of the previous Novartis collaboration project, contributing 0.183 billion US dollars to the total revenue of the same period last year. By the end of the third quarter of 2024, through adjustments.
BeiGene Shares Are Trading Lower. The Company Reported Q3 Financial Results.
10-Q: Quarterly report
In the third quarter, beigene (06160.HK) narrowed its GAAP operational loss to 0.121 billion US dollars.
Beigene (06160.HK) announced its third-quarter performance ending in September, with total revenue of 1.002 billion US dollars according to US GAAP, an increase of 28.2% year-on-year. This was mainly driven by sales growth of Bei Yuze in the USA and Europe, increasing by 87% and 217% respectively. GAAP operating losses decreased from 0.134 billion US dollars in the same period last year to 0.12 billion US dollars. During the quarter, adjusted operating profit recorded 65.63 million US dollars, achieving non-GAAP operating profit for two consecutive quarters, compared to an adjusted operating loss of 16.34 million US dollars in the same period last year. GAAP net loss was 0.121 billion US dollars, compared to the previous year
Health Check: How Prudently Does BeiGene (NASDAQ:BGNE) Use Debt?
BeiGene Shenzhou Ltd. Third Quarter Report 2024
No Data
No Data